DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Assessment of nanOss Bioactive 3D in the Posterolateral Spine

Information source: Pioneer Surgical Technology, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Degenerative Disc Disease; Spinal Stenosis; Spondylolisthesis

Intervention: nanOss Bioactive 3D BVF (Device)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Pioneer Surgical Technology, Inc.

Official(s) and/or principal investigator(s):
Stephen Robbins, MD, Principal Investigator, Affiliation: Milwaukee Spinal Specialists

Summary

Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process. nanOss Bioactive 3D is approved for use in the U. S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.

Clinical Details

Official title: A Prospective, Post-Market Assessment Of NanOss Bioactive 3D in the Posterolateral Spine

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of patients with fusion

Secondary outcome:

Number of participants with improvement in physical disability

Number of participants with improvement in quality of life

Number of participants with improvement in pain scores

Number of participants with decreased usage of pain medication

Returning to work

Satisfaction with surgery

Detailed description: The post market clinical investigation is designed to assess instrumented PLF using nanOss Bioactive 3D bone void filler with autograft bone and bone marrow aspirate in patients with symptomatic spinal stenosis secondary to degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1 characterized by the inclusion and exclusion criteria. Patients will be evaluated at Preop, discharge, 6 and 12 months. X-rays will be obtained at each visit; Additionally, a CT scan will be performed at the 12 month postoperative visit to assess fusion status.

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- At least 21 years of age and skeletally mature.

- Symptomatic spinal stenosis secondary to DDD with up to Grade 1 spondylolisthesis at

one or two adjacent levels from L2-S1 requiring instrumented PLF surgery.

- Completed a minimum of 6 months of non-operative treatment.

- Pre-operative objective evidence of primary diagnosis confirmed by appropriate

imaging studies (AP, Lateral, Flexion and Extension images and an MRI or CT scan).

- Is willing and able to return for post-treatment exams according to the follow-up

called for in the protocol.

- Is able to review, understand and sign the informed consent document.

Exclusion Criteria:

- Symptomatic at more than two levels.

- Has had previous fusion surgery at the level(s) to be treated (previous discectomy,

laminotomy, laminectomy or nucleolysis at the level(s) to be treated < 6 months ago is ok).

- Has > 11 degrees lumbar scoliosis.

- Has > 40 BMI.

- Has > Grade 1 spondylolisthesis.

- Has osteoporosis (T-score of -2. 5 or below), osteomalacia, Paget's disease or

metabolic bone disease.

- Has a disease that significantly inhibits bone healing (e. g., diabetes type 1, renal

failure, impaired calcium metabolism).

- Has a medical condition that requires or has a history of chronic steroid use (i. e.,

oral steroids), with the exception of inhaled/nasal corticosteroids steroids or has any medical condition that requires treatment with drugs known to interfere with bone healing.

- Has a neurological disease (e. g., Parkinson's disease), a psychosocial disorder

(e. g., suicidal, diminished capacity) or has a history of substance abuse which would preclude accurate evaluation or limit the ability to comply with study requirements.

- Has either an active infection or infection at the site of surgery

- Has a systemic disease (e. g., AIDS, HIV, active hepatitis, tuberculosis)

- Has rheumatoid arthritis or other autoimmune disease.

- Has spinal tumors.

- Has an active malignancy (except non-melanoma skin cancer) or history of any invasive

malignancy unless treated and in remission for at least five years.

- Has a known sensitivity or allergies to porcine collagen, PEEK, tantalum or titanium.

- Has active arachnoiditis.

- Has fractures of the epiphyseal plate or fractures for which stabilization of the

fracture is not possible.

- Is a prisoner.

- Is involved in spinal litigation at the treated level(s).

- Is participating in another clinical study that would confound Study data.

- Is pregnant or is interested in becoming pregnant while participating in the

Study.

Locations and Contacts

MUSC Neurosurgery & Spine Services, Charleston, South Carolina 29425, United States

Milwaukee Spinal Specialists, Glendale, Wisconsin 53212, United States

Additional Information

Starting date: April 2013
Last updated: July 17, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017